Table 3 Differentially methylated regions between the DHA-supplemented and control group at birth

1

chr3:138152837-138153763

12

926

ESYT3

TSS1500,TSS200,1stExon,5′UTR

5.75E−15

−0.045

Y

2

chr12:132293329-132293702

5

373

Intergenic

1.12E−07

−0.026

Y

3

chr15:34610829-34611069

4

240

SLC12A6

Body,1stExon,5′UTR,TSS200

4.99E−06

−0.011

Y

4

chr3:42306150-42307193

10

1043

CCK

5′UTR,1stExon,TSS200,TSS1500

6.05E−06

−0.012

Y

5

chr7:1882776-1883876

9

1100

MAD1L1

Body

8.75E−06

0.023

Y

6

chr2:48844728−48845068

8

340

GTF2A1L, STON1

TSS1500,Body,TSS200,1stExon,5′UTR

8.75E−06

−0.019

Y

7

chr6:166876490-166877038

7

548

RPS6KA2

Body

8.75E−06

0.022

Y

8

chr8:59058254-59058585

3

331

FAM110B

5′UTR

9.79E−06

−0.009

N

9

chr10:134221633-134222453

6

820

PWWP2B

3′UTR,Body

1.10E−05

−0.033

Y

10

chr3:42201314-42201898

6

584

TRAK1

TSS1500,Body,TSS200,1stExon

2.11E−05

−0.015

N

11

chr6:150346721-150347053

10

332

RAET1L

TSS200,TSS1500

5.41E−05

−0.009

Y

12

chr12:7781004-7781431

5

427

Intergenic

2.15E−04

−0.044

Y

13

chr6:1619162-1619687

3

525

Intergenic

2.62E−04

−0.012

N

14

chr8:117950244-117950504

7

260

C8orf85

TSS1500,TSS200,1stExon,5′UTR

4.08E−04

−0.01

N

15

chr4:62382932-62383240

4

308

LPHN3

Body

6.20E−04

−0.019

N

16

chr4:1107202-1107259

2

57

RNF212

1stExon,5′UTR

6.45E−04

−0.01

N

17

chr17:75446431-75446661

6

230

SEPT9

TSS200,Body,1stExon,5′UTR

7.94E−04

−0.013

N

18

chr6:31549929-31550090

2

161

LTB

Body,1stExon

8.92E−04

−0.008

N

19

chr22:32599511-32599516

2

5

RFPL2

TSS200,5′UTR,TSS1500

9.17E−04

−0.037

Y

20

chr20:13620031-13620048

2

17

TASP1

TSS1500

9.61E−04

0.012

N

21

chr1:156261200-156261207

2

7

TMEM79

Body

9.77E−04

0.01

N